Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: A retrospective analysis
| Autor: | Nobuhisa Kanahara, Tomihisa Niitsu, Masumi Tachibana, Masatomo Ishikawa, Masaomi Iyo, Motoki Watanabe, Tasuku Hashimoto |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Psychosis medicine.medical_specialty medicine.drug_class Dopamine medicine.medical_treatment Global Assessment of Functioning Drug Resistance Atypical antipsychotic Piperazines 03 medical and health sciences 0302 clinical medicine Piperidines Internal medicine Outcome Assessment Health Care Brief Psychiatric Rating Scale medicine Humans Psychiatry Antipsychotic General Psychology Retrospective Studies Psychiatric Status Rating Scales Blonanserin General Medicine Middle Aged medicine.disease 030227 psychiatry Psychiatry and Mental health Tolerability Schizophrenia Female Psychology 030217 neurology & neurosurgery Antipsychotic Agents medicine.drug |
| Zdroj: | Asian Journal of Psychiatry. 24:28-32 |
| ISSN: | 1876-2018 |
| DOI: | 10.1016/j.ajp.2016.08.014 |
| Popis: | Objective Dopamine supersensitivity psychosis (DSP) is one of the key factors contributing to the development of antipsychotic treatment-resistant schizophrenia (TRS). We investigated the efficacy of blonanserin, an atypical antipsychotic, for patients with TRS and DSP. Methods In this 12-month retrospective follow-up study, we investigated the cases of eight consecutive patients with unstable TRS and DSP treated with blonanserin as an add-on therapy. We examined changes in scores for the Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression-Severity of Illness (CGI-S) scale and the Global Assessment of Functioning scale (GAF) during the 12 months after the administration of blonanserin. Results The patients’ total scores on the BPRS and GAF scores were significantly improved by 3 months at the latest. Positive BPRS and CGI-S scores were also improved by 6 months at the latest. The total chlorpromazine-equivalent doses of antipsychotics were significantly reduced from 1462.3 ± 499.6 mg to 794.1 ± 642.8 mg (p = 0.001) after 12 months of blonanserin treatment, with a favorable safety and tolerability profile. Conclusions Blonanserin may be a promising antipsychotic for the treatment of TRS and DSP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect